key: cord-0987561-yz0iam8o authors: Castillo‐Olivares, Javier title: African horse sickness in Thailand: Challenges of controlling an outbreak by vaccination date: 2020-10-02 journal: Equine Vet J DOI: 10.1111/evj.13353 sha: 6ddfc4d3ab1691713065ba6a833a866e22bf6fa7 doc_id: 987561 cord_uid: yz0iam8o nan horse deaths, bringing the mortality rates above 90%. This is the first ever outbreak of AHS in Thailand and the first occurrence of AHS in Asia in some 60 years. In the absence of AHS occurring in neighbouring countries in decades, the emergence of AHS thousands of miles away from endemic regions for the disease, it is likely that the Thai outbreak has its origins in the importation of AHS-infected animals. Thailand is a non-endemic country for AHS and consequently its whole equine population is immunologically naive to the virus and therefore highly susceptible to the severe clinical manifestations of the disease. The hot and humid climate of Thailand, with the absence of cold winters that would interrupt the activity of Portugal, the virus spread to Portugal in 1989. 5 It was only after vigorous and comprehensive control measures, which included widespread vaccination, control of animal movements, insect control and rigorous sero-surveillance, that this outbreak was finally eradicated. It is likely, that the mild and short winters in the South of the Iberian Peninsula contributed to the presence of AHS in that part of the world for consecutive seasons. AHS is a lethal disease that can spread rapidly within an equine population, has a high negative economic impact in countries where it occurs and affects dramatically international trade of horses. For all these reasons AHS is one of the listed diseases of the OIE (World Organisation for Animal Health) 6 and is the only equine infectious disease for which the OIE issues an official recognition of disease freedom for a country or parts thereof (OIE, Terrestrial Animal Health Code). 7 The loss of the AHS-freedom status is already affecting Thailand and the same will happen to neighbouring countries should AHS spread in the region. As a consequence, horse exports will be severely restricted, for example horse exports to the EU will be banned for 2 years. 8 with the rest of the world will require sound active and passive disease surveillance strategies, using appropriate and validated diagnostic methods. This is a task that requires efficient coordination of the veterinary services and authorities both at national and international levels. The logical diversion of national funding efforts to combat the current COVID-19 pandemic will undoubtedly play a detrimental role in the capacity to curtail the expansion of AHS in the region. Vaccination is an essential pillar of any AHS control programme and it needs to be implemented in conjunction with other control measures such as rapid accurate diagnosis, disease surveillance, preven- With regards to the current outbreak, these dilemmas are not only for Thailand to consider, but also for neighbouring countries that are threatened by the spread of AHS in their territories and are monitoring this outbreak. It is being reported that Cambodia and China are already testing horses for AHS. 12 The pre-emptive use of current licensed vaccines in Thailand's neighbouring countries will inevitably result in loss of the AHSfreedom status and will result in economic losses due to trade restrictions. Surveillance of disease and infection using diagnostic tests validated according to international standards recommended by the OIE will play an essential role in the control of the current outbreak. Rapid accurate diagnostic tests play a critical role in disease con- Considering that vaccination is currently being used in Thailand, the strategy for disease surveillance is going to play a vital role in controlling this outbreak but adaptation of existing tests to the current epidemiological context would be necessary for improved control. As discussed earlier, the decision to vaccinate against AHS in a non-en- Due to the drawbacks of the LAV (especially, the risk of reversion to virulence and genome segment re-assortment between vaccine and field virus), AHS research has consistently focused on finding alternative vaccine strategies that are safer and more efficacious. 13 and some of these specific tests have been very rigorously tested and reached Stage III of the OIE validation pathway, [14] [15] [16] In terms of efficacy, baculovirus expressed VP2/VP5 sub-unit vaccines have been demonstrated to induce virus neutralising antibodies and protection in laboratory rodents and also in horses, 25, 26 It is believed that they did not reach the market due to the high costs of manufacturing in an industrial setting. However, recent studies demonstrated that vaccine production yields can be improved significantly and that at least in the mouse model, protection can be achieved with just one vaccine dose. 27 Canarypox-based vaccines expressing AHSV-VP2/ VP5 have also shown promising results in horses, at least with AHSV serotype 4, demonstrating both cellular and humoral protective immune responses could be induced. 28, 29 Likewise, AHSV-VP2 vaccines based on recombinant modified Vaccinia Ankara virus (MVA) were shown to be protective in small animal models and in horses and it was shown that the main protective mechanism was mediated by virus neutralising antibodies. [30] [31] [32] [33] [34] [35] Furthermore, the potential to use this strategy as a polyvalent approach was also demonstrated. 36 With regards to safety, in contrast with attenuated vaccines, the Thus, all three vaccine technology platforms are suitable for industrial production, have an excellent track record of safety and have proven efficacy in the field. Any of these three vaccine platforms represent a realistic prospect for development and commercialisation of a safe, efficacious and DIVA compatible AHS vaccine. They also present the advantage that they are compatible with one another since they are based on the same protective antigens (i.e. AHSV-VP2). AHS is a truly devastating disease from both an animal welfare perspective and in respect of the economic damage that it causes. The virus is endemic to Sub-Saharan Africa but historically has emerged periodically in Southern Europe, North Africa, the Arabian Peninsula, the Middle East, Iran and India. Today it is causing a serious outbreak in Thailand, threatening the whole region. The European experience with bluetongue, a disease of ruminants that has become endemic in this continent and is caused by a virus closely related to AHSV and transmitted by the same insect vectors, is a serious reminder of what could potentially occur with AHS in South-East Asia. The spread of AHS and possible endemicity of AHSV in Asia is particularly worrying due to the lack of safe and effective vaccines able to control the disease without expensive and time-consuming additional disease management measures. The control of the current outbreak in Thailand and limitation of its wider spread in Asia will be challenging. The use of the polyvalent live attenuated vaccine, which contains in its formulation attenuated viruses of several AHSV serotypes other than AHSV type 1, will require careful design of disease surveillance protocols. Besides the implementation of vaccination with the live attenuated vaccine, the International Horse Sports Confederation (IHSC) is focusing its support on the development of polyvalent whole virus inactivated vaccines, 43 which may prove sub-optimal due to the limited DIVA capability and unknown protective efficacy for AHSV-1. Therefore, at present, imme- Control and eradication of African horse sickness with vaccine African horse sickness in Spain African horse sickness in Portugal: A successful eradication programme Implementing Regulations (EU) 2020/485 of 2 April 2020 amending Annex I to Implementing Regulation EU 2018/659 as regards the entry into the Union of live equidae and of semen, ova and embryos of equidae from Thailand us-china -horse s-disea se/china -to-test-horse s-in-borde r-areas -for-afric an-horse -sickn ess-idUSK CN2251CB Real-time fluorogenic reverse transcription polymerase chain reaction assay for detection of African horse sickness virus Diagnostic accuracy of a duplex real-time reverse transcription quantitative PCR assay for detection of African horse sickness virus Assessment of reproducibility of a VP7 Blocking ELISA diagnostic test for African horse sickness African horse sickness in naturally infected, immunised horses Dynamics of African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial polyvalent live attenuated vaccine African Horse Sickness: A Review of Current Understanding and Vaccine Development African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform. Vaccine Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge Immunogenicity of plant-produced African horse sickness virus-like particles: implications for a novel vaccine Plant-produced chimeric virus-like particles -A new generation vaccine against African horse sickness Synthesis of empty African horse sickness virus particles The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA). PLoS One A Modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR 2/2 mouse model Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination The use of a recombinant canarypox-based equine influenza vaccine during the 2007 Australian outbreak: A systematic review and summary A vaccine for the prevention of HPV 16, 18-associated cervical cancer Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data from a Phase 1 Randomized Clinical Trial in Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial How to cite this article: Castillo-Olivares J. African horse sickness in Thailand: Challenges of controlling an outbreak by vaccination